PARP1 and cervical squamous intraepithelial neoplasia: Our results suggest that the clinical use of PARP1 inhibitors should be extended beyond those tumors with BRCA mutations to a larger group of patients with PTEN mutant tumors, maybe even to the larger group of CIN high tumors.